ClinicalTrials.gg
CompletedNCT04434768Updated Sep 23, 2026

Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke

A Phase 1 interventional study of UMSC01 in Acute Stroke, sponsored by Ever Supreme Bio Technology Co., Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Ever Supreme Bio Technology Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 394 studies in Stroke with a site in Taiwan — 73 open to participants now, 83 under way, 4 of them phase 3. Stroke · Taiwan.

Enrollment
315th of 337
10 · median 54
Started
2020
with 29 others
Phase 1
9 of 394
none open now
Registered
231st of 394
by date

Among the 394 studies in Stroke with a site in Taiwan, this one is the 315th largest by enrollment of the 337 interventional ones that give a count, is one of 30 that started in 2020, is one of 9 in phase 1, and was the 231st registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

73 of the 394 studies in Stroke with a site in Taiwan are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 394 studies in Stroke with a site in Taiwan, or all of them as a file.
02

Study summary

This study is a first-in-human assessment of safety of using umbilical cord mesenchymal stem cells (UCMSCs) in patients with Acute Ischemic Stroke via a combination of intra arterial (IA) and intravenous (IV) stem cell administration. The novelty of the current UMSC01 treatment study is the dual route of administration. Since dual administration of UCMSC via IA and IV had never been conducted in humans, there may be unknown risks to humans not predicted from the preclinical studies. However, the risk to patients in this trial will be minimized by rigorous adherence to the eligibility criteria, use of appropriate dose and concentration of stem cells, standardized techniques of stem cell infusion, and intensive patient monitoring during and after stem cell infusion.

Read the detailed description

Each year about 700,000 people experience a new or recurrent stroke in the United States.Stroke is a leading cause of death, along with cancer and coronary heart disease, and the most common cause of physical disability in adults. Moreover, stroke causes a greater loss of healthy life years, as measured in disability adjusted life years, than other diseases.

This product is a new cell therapy product for treating Stroke and produced by Ever Supreme Bio Technology Co., Ltd in Taiwan. For animal studies, UMSC01 has been demonstrated its effectiveness for acute myocardial infarction (AMI) and stroke. The UMSC01 has been demonstrated its effective effect in the animal models of stroke in the current studies. The acute stroke rats receiving intracerebral UMSC01 transplantation showed significantly improved neurological function compared to vehicle-treated control rats.

03

Conditions studied

  • Acute Stroke

Browse trials for

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Donor-Inclusion Criteria:

  1. Pregnant women who are aged ≥ 20, \<50 years old on the date of consent.
  2. Pregnant women who are willing to and has given her signed written .
  3. Pregnant women whose gestation age ≥ 34 weeks and have intact placenta.
  4. Pregnant women who have not had any complication of pregnancy.
  5. Pregnant women who are willing to provide a personal and family medical history (as much available) of herself and the biologic father (as much available), prior to or following collection of the umbilical cord.

Donor-Exclusion Criteria:

  1. Pregnant women who have clinically severe and/or life threatening disease(s) such as uncontrolled diabetes mellitus (fasting sugar level > 250 mg/dL) and malignant tumor.
  2. Pregnant women who have been tested positive for the following tests within 7 days before or after umbilical cord acquirement:

    • -1 (HIV-I): anti- HIV-I and nucleic acid test (NAT)
    • HIV-II
    • virus (HBV): Hepatitis B surface antigen (HBsAg), anti- Hepatitis B core (HBc) and NAT
    • virus (HCV): anti-HCV and NAT
    • Cytomegalovirus (CMV)
    • Treponema pallidum
    • Chlamydia trachomatis
    • Neisseria gonorrhea
    • Human T cell leukemia virus-I/II (HTLV-I/II)
    • West Nile virus (WNV) NAT
  3. Pregnant women are with increased risk for Creutzfeldt-Jakob disease (CJD) if you have received a non-synthetic dura mater transplant, human pituitary-derived growth hormone, or have one or more blood relatives diagnosed with CJD.
  4. Pregnant women had spent three months or more cumulatively in the United Kingdom (U.K) from the beginning of 1980 through the end of 1996; or had received any transfusion of blood or blood components in the U.K. or France between 1980 and the present; or lived 5 years or more cumulatively in Europe.
  5. Pregnant women or her sexual partners were born or lived in certain countries in Africa (Cameroon, Central African Republic, Chad, Congo, Equatorial Guinea, Gabon, Niger, or Nigeria) after 1977 (risk factor for HIV group O).
  6. Pregnant women who have medical diagnosis of Zika virus (ZIKV) infection or residence in, or travel to, an area with active ZIKV transmission (according to the list from Centers for Disease Control and Prevention. Zika Virus: Areas with Zika) at any point during that pregnancy.
  7. Pregnant women who have sex at any point during that pregnancy with a male who is known to medical diagnosis of ZIKV infection or residence in, or travel to, an area with active ZIKV transmission.
  8. Pregnant women who have received blood infusion or stayed for more than 3 months in WNV potential countries.
  9. Pregnant women who have unexplained post-donation febrile illness with headache or other symptoms suggestive of WNV infection (i.e., flu-like symptoms that include fever with headache, eye pain, body aches, generalized weakness, new skin rash or swollen lymph nodes or other evidence of WNV infection) within two weeks.
  10. Pregnant women who have medical history of tuberculosis.
  11. Pregnant women who have medical history of malignant tumor.
  12. Fetuses that have found with genetic disease in prenatal checkups.
  13. Pregnant women who would like to store cord blood or umbilical cord cells, other than this study usage.
  14. Pregnant women who are not suitable to donate as judged by the Investigator(s).

Subject-Inclusion Criteria:

  1. Male or female who are age ≥ 20, ≤80 years old on date of consent.
  2. Patients who have had a recent (onset within the past 36 hours) acute ischemic stroke in the unilateral middle cerebral artery (MCA) distribution (M1 and M2). The location of ischemic stroke should be diagnosed by magnetic resonance image (MRI).
  3. Patients who have National Institutes of Health Stroke Scale (NIHSS) score of 8 to 17 with both motor arm and motor leg scores ≥ 3 (MRC scale).
  4. Patients who have Glasgow Coma Scale (GCS) score of > 8 on the date of consent.
  5. Patients who have modified Rankin Scale (mRS) of 2\~4 on the date of consent and their mRS prior to stroke onset should be 0 or 1 (either by self-reported history or by family/caregiver report).
  6. Patients who have stable vital signs for at least 24 hours, defined as normal respiration, afebrile and mean arterial pressure ≤ 180 mmHg.
  7. Patient's random blood sugar \<350 mg/dl and > 50 mg/dl and normal urea/ electrolytes.
  8. Patient has appropriated blood clotting function as assessed by the following laboratory requirements: PT, ≤ 1.5X (ULN).
  9. Patients are willing to sign informed consent or assent by the next of kin.
  10. All male patients and female patients with (between puberty and 2 years after menopause) should use appropriate method(s) shown below, for at least 4 weeks after UMSC01 treatment.

    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception).
    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    3. Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject.
    4. Combination of any two of the following listed methods: (d.1+d.2 or d.1+d.3, or d.2+d.3)

      • d.1 Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.
      • d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS).
      • d.3 Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with Spermicidal foam/gel/film/cream/vaginal suppository.

Subject-Exclusion Criteria:

  1. Patients with recurring stroke attack within 6 months before this current stroke episode.
  2. Patients with signs of midline shift, hemorrhagic transformation or fluctuation of symptoms.
  3. Patients who have participated in other studies and received any treatment within 4 weeks prior to receiving UMSC01.
  4. Patients who have immuno-compromised condition,or are with known clinically significantly conditions or are receiving treatments.
  5. Patients who are unable to undergo brain Single-photo Emission Computed Tomography (SPECT), CT, MRI and PET scans for any reason.
  6. Patients with inadequate hepatic and renal function after onset of acute ischemic stroke: (AST) and Alanine aminotransferase (ALT) ≥ 5 x upper limit of normal (ULN); estimated (eGFR) \< 30 mL/min at screening.
  7. Patients who have medical history of malignant tumor, spinal injury or other neurological diseases that will confound the evaluation of this study.
  8. Patients who have clinically active peripheral nephropathy, myopathy or other clinically significant neurological diseases that will confound the evaluation of this study.
  9. Patients who have a difference in NIHSS score ≥ 5 between the time beginning hospitalization and investigational product (IP) treatment.
  10. Patients who are diagnosed of heart failure with a (NYHA) score of III or IV.
  11. Patients not suitable to participate the trial as judged by the investigator(s).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    UMSC01

    UMSC01 cells mixed with normal saline will be administered to patients after the onset of stroke.

    Biological: UMSC01

Interventions

  • BiologicalUMSC01

    There will be one dose of IV administration in patients with acute ischemic stroke, or one dose of IV administration followed by low or high doses of IA infusion for acute ischemic stroke with or without bridging therapy (i.e. Intravenous rt-PA thrombolysis or intraarterial thrombectomy) with 12 months of follow up after the first treatment.

06

What researchers measure

Primary outcomes

  1. SAE incidences over the study period

    Incidence of SAEs will be presented by coding system. The coding system used will be the MedDRA

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

  2. SUSAR incidences over the study period

    Incidence of SUSARs will be presented by coding system. The coding system used will be the MedDRA.

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

  3. TEAE incidences over the study period

    Incidence of TEAEs will be presented by coding system. The coding system used will be the MedDRA

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

Secondary outcomes

  1. Changes of Glasgow Coma Scale (GCS; Score range: Max.15, Min. 3) from Baseline Visit (Visit 1) to subsequent scheduled visits

    Net change of Glasgow Coma Scale (Score Range: 3\~15; the higher score the better outcome) from baseline visit to subsequent visits will be summarized by descriptive statistics

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

  2. Changes in National Institute of Health Stroke Scale (NIHSS; Score Range: 0~42; the higher score the worsen outcome) from Baseline Visit (Visit 1) to subsequent scheduled visits

    Net change of NIHSS (Score Range: 0\~42; the higher score the worsen outcome) from baseline visit to subsequent visits will be summarized by descriptive statistics

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

  3. Changes in mRS from Baseline Visit (Visit 1) to subsequent scheduled visits.

    The transition (improved, stable, and worsened) from baseline visit to subsequent visits will be summarized by descriptive statistics

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

  4. Changes in FMT from Baseline Visit (Visit 1) to subsequent schedules visits

    Net change of FMT from baseline visit to subsequent visits will be summarized by descriptive statistics.

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

  5. Changes in BI from Baseline Visit (Visit 1) to subsequent schedules visits

    Net change of BI from baseline visit to subsequent visits will be summarized by descriptive statistics

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

  6. Change and ratios of MRI image from baseline to subsequent scheduled visits

    Net change of infarcted area in the brain will be summarized by descriptive statistics.

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

  7. Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits

    Net change of mean transit time (MTT) presented in second and the ratio of MTT between the affected and unaffected hemispheres will be summarized by descriptive statistics

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

  8. Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits

    Net change of cerebral blood flow (CBF)(presented in ml/100g/min) and the ratio of CBF between the affected and the unaffected hemisphere will be summarized by descriptive statistics.

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

  9. Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits

    Net change of cerebral blood volume (CBV)(present in mL/100g) and the ratio of CBV between the affected and the unaffected hemisphere will be summarized by descriptive statistics.

    Time frame: From "baseline visit, prior to the investigational product administration" to "24 weeks"

07

Study locations

1 site
  • China Medical University Hospital
    Taichung, Non-US 404, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jan 2026, 61 months.

Of 26 industry-sponsored phase 1 interventional studies under Stroke, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 61 months is above that.

Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2020
First posted
Jun 17, 2020
StartActual
Dec 2, 2020
Primary completionActual
Jan 23, 2026
CompletionActual
Jan 23, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04434768
Lead sponsor
Ever Supreme Bio Technology Co., Ltd.
Responsible party
Sponsor
First posted
Jun 17, 2020
Start date
Dec 2, 2020
Primary completion
Jan 23, 2026
Completion
Jan 23, 2026
Last update
Sep 23, 2026

Study contacts

Chon-Haw Tsai, MD
principal investigator · Attending Physician of study site

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion